EGFR and non-small cell lung carcinoma: Previous studies have demonstrated better therapeutic outcomes and fewer toxic effects via EGFR-TKIs compared with the traditional chemotherapies in patients with non-small cell lung cancer (NSCLC) and EGFR mutations [5–8].